Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) reported Q1 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31). Revenue for the quarter came in at $111.6 million versus the consensus estimate of $98.02 million.

GUIDANCE:

Mirum Pharmaceuticals, Inc. sees FY2025 revenue of $435-450 million, versus the consensus of $427.8 million.

For earnings history and earnings-related data on Mirum Pharmaceuticals, Inc. (MIRM) click here.